Insight

Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial

Photo of article from nejm.org

Apr 14, 2024, 22:26

Sergio Cifuentes Canaval: Wu Y-L et al. have just released the results of a preplanned interim analysis from the ALINA trial

Sergio Cifuentes Canaval, Cancer Research Project Manager at

“Exciting news from the ALINA trial! Alectinib, an oral tyrosine kinase inhibitor, has shown remarkable results in resected ALK-positive NSCLC. Patients receiving alectinib had a 76% lower risk of disease recurrence or death compared to chemotherapy. Promising outcomes with a low-grade safety profile.

Wu Y-L et al. have just released the results of a groundbreaking preplanned interim analysis from the **ALINA trial**.

Phase III, patients with resected ALK NSCLC
257 patients stages IB, II, or IIIA
Randomly 1:1 to Alectinib 2 years vs Platinum-Based Chemotherapy for four cycles
Primary Endpoint: DFS
Median follow-up of 27.8 months, alectinib with a 76% lower risk of disease recurrence or death compared to chemotherapy

Implications:

Alectinib represents a paradigm shift in the battle against early-stage, resectable ALK-positive lung cancer.
It not only improves patient outcomes but also reduces the risk of disease recurrence.”

Source: Sergio Cifuentes Canaval/LinkedIn

alectinib ALINA trial ALK-positive NSCLC cancer CENEIT México Lung cancer OncoDaily Oncology platinum-based chemotherapy Sergio Cifuentes Canaval tyrosine-kinase inhibitor Wu Y-L

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage